The effects of leukemia and lymphoma chemotherapy on hematopoietic cells.
D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000145:classification; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000477:Alkylating Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D005938:Glucocorticoids; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D001215:Asparaginase; D006918:Hydroxyurea; D003630:Daunorubicin